Arcturus Therapeutics Holdings Inc.

NasdaqGM ARCT

Arcturus Therapeutics Holdings Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2024: 104.50%

Arcturus Therapeutics Holdings Inc. Gross Profit Margin is 104.50% for the Trailing 12 Months (TTM) ending September 30, 2024, a 85.17% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

Arcturus Therapeutics Holdings Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was 56.44%, a 129.06% change year over year.
Arcturus Therapeutics Holdings Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was -194.18%, a 88.95% change year over year.
Arcturus Therapeutics Holdings Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was -1,757.47%, a -411.48% change year over year.
Arcturus Therapeutics Holdings Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2020 was -343.61%, a -7,869.80% change year over year.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

NasdaqGM: ARCT

Arcturus Therapeutics Holdings Inc.

CEO	Mr. Joseph E. Payne M.Sc.
IPO Date	May 22, 2013
Location	United States
Headquarters	10628 Science Center Drive
Employees	180
Sector	Health Care
Industries Pharmaceuticals Biotechnology Vaccines

Description

Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.

Key trends

Past 5 years